Bioatla Inc

$0.32
(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Bioatla Inc

Stock Price
$0.32
Ticker Symbol
BCAB
Exchange
NASDAQ

Industry Information for Bioatla Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Bioatla Inc

Website
https://www.bioatla.com
Country
USA
Full Time Employees
61

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Fundamentals for Bioatla Inc

Market Capitalization
$18,910,276
EBITDA
$-73,018,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.44
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
58,401,100
Percent Owned by Insiders
9.59%
Percent Owned by Institutions
48.57%
52-Week High
52-Week Low

Technical Indicators for Bioatla Inc

50-Day Moving Average
200-Day Moving Average
RSI
47.2
ATR
0.04

Analyst Ratings for Bioatla Inc

Strong Buy
1
Buy
1
Hold
1
Sell
0
Strong Sell
0

News About Bioatla Inc

Mar 27, 2025, 4:05 PM EST
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitors Cash balance of $49mm at year-end 2024 with recent cost-reduction measures expected to further extend runway beyond key clinical readouts in 1H 2026 Management to host conference call and webcast today at 4:30 PM Eastern Time See more.
Mar 20, 2025, 8:00 AM EST
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. See more.
Oct 20, 2024, 4:06 PM EST
We recently compiled a list of the Michael Burry's Top 10 Stock Picks Heading into 2025. See more.
Aug 14, 2024, 4:32 PM EST
Investing.com - Michael Burry, the hedge fund manager famous for his 2008 bet against the US housing market depicted in "The Big Short," has further increased his stake in Alibaba Group Holdings Ltd ADR (NYSE:BABA) while significantly cutting his overall equity portfolio in half during the second quarter. See more.